Esperion Therapeutics | ESPR - Interest Expense On Debt


Esperion Therapeutics reported $22.64M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amarin USD 3K 5K Dec/2024
Amgen USD 657M 4M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Cipla INR 131.3M 9M Mar/2026
CSL USD 215M 111M Dec/2025
Cytokinetics USD 33.34M 3M Mar/2026
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Geron USD 7.15M 150K Mar/2026
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Merck USD 479M 67M Mar/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 11.49B 36B Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Pfizer USD 671M 40M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Sanofi EUR 178M 203M Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025